Famitinib

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gastroenteropancreatic Neuroendocrine Tumor

Conditions

Gastroenteropancreatic Neuroendocrine Tumor

Trial Timeline

Oct 1, 2011 → May 1, 2016

NCT ID

NCT01994213

About Famitinib

Famitinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Gastroenteropancreatic Neuroendocrine Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT01994213. Target conditions include Gastroenteropancreatic Neuroendocrine Tumor.

What happened to similar drugs?

0 of 3 similar drugs in Gastroenteropancreatic Neuroendocrine Tumor were approved

Approved (0) Terminated (0) Active (3)

🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

🔄68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3

🔄Lanreotide autogelIpsenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05473468	Phase 1	UNKNOWN	Aug 26, 2022	Nov 1, 2022	Healthy Subjects
NCT04479904	Phase 2	Withdrawn	Aug 10, 2020	Feb 10, 2022	Intrahepatic Cholangiocarcinoma
NCT01762293	Phase 2	Completed	Apr 1, 2012	Oct 1, 2014	Colorectal Cancer
NCT02336724	Phase 2	UNKNOWN	Mar 1, 2012	Jun 1, 2019	Gastrointestinal Stromal Tumor
NCT01994213	Phase 2	Terminated	Oct 1, 2011	May 1, 2016	Gastroenteropancreatic Neuroendocrine Tumor
NCT01392235	Phase 2	Completed	Jul 1, 2011	Aug 1, 2016	Recurrent Nasopharyngeal Carcinoma

Competing Products

9 competing products in Gastroenteropancreatic Neuroendocrine Tumor

See all competitors

Product	Company	Stage	Hype Score
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	47
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	47
Lanreotide + Pembrolizumab	Merck	Phase 1/2	32
Lutathera + Gallium 68 Dotatate	Novartis	Phase 1	36
Lutathera®	Novartis	Pre-clinical	30
Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus	Novartis	Phase 1	29
Lanreotide Autogel 120 mg + Temozolomide (TMZ)	Ipsen	Phase 2	32
satoreotide trizoxetan	Ipsen	Phase 1/2	29
Lanreotide autogel	Ipsen	Phase 3	37